NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR M701 “CD3/EpCAM BISPECIFIC ANTIBODY”

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF CAFELKIBART “CCR8 MONOCLONAL ANTIBODY” FOR SECOND-LINE GASTRIC CANCER

VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF CULMERCICLIB CAPSULE “CDK2/4/6 INHIBITOR” FOR FIRST-LINE TREATMENT OF BREAST CANCER APPROVED FOR MARKETING

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN